



This is a repository copy of *Comparative analysis of marketed factor VIII products: comment.*

White Rose Research Online URL for this paper:
<http://eprints.whiterose.ac.uk/138487/>

Version: Accepted Version

Article:

Makris, M. orcid.org/0000-0001-7622-7939 and Farrugia, A. (2018) Comparative analysis of marketed factor VIII products: comment. *Journal of Thrombosis and Haemostasis*. ISSN 1538-7933

<https://doi.org/10.1111/jth.14321>

This is the peer reviewed version of the following article: Makris, M. and Farrugia, A. (2018), Comparative analysis of marketed factor VIII products: comment. *J Thromb Haemost.*, which has been published in final form at <https://doi.org/10.1111/jth.14321>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

We read with interest the paper by Anzengruber and colleagues recently published in the journal. The authors reported significant variation among the different recombinant concentrates in terms of content of soluble protein aggregates and subvisible particles(1). This could be important in explaining the differential immunogenicity, in terms of inhibitor development, among recombinant concentrates.

We were, however, disappointed that the authors do not name the nine brands of recombinant FVIII concentrates they studied. By convention in scientific literature, authors are required to name their reagents and their source. We can not see any reason why the names of the concentrates were withheld and invite the authors to name the products now. This is particularly relevant as the studies cited by Anzengruber et al to demonstrate the different rates of inhibitor incidence relative to product type do cite the products used (2), (3). A similar level of disclosure would have enhanced the relevance of Anzengruber et al's study and contributed to guiding therapeutic choice.

Without naming the products, all one can conclude is that there is variation between the products but by naming them the scientific community can correlate the results with other observations about specific concentrates. We note that, in order to differentiate their particular products and leverage market advantage, some products are acquiring approval from regulatory agencies by validating conditions, including storage at room temperature (4), which may well precipitate the kind of environmental pressure which generates the changes reported by Anzengruber et al (5). It would seem that the kind of analytes studied in their paper should be considered for the purpose of product quality control, but for this to be considered by authorities full information is required.

Mike Makris

Professor of Haemostasis and Thrombosis, University of Sheffield

Albert Farrugia

Adjunct Professor, School of Surgery, University of Western Australia

References:

1. Anzengruber J, Lubich C, Prenninger T, Gringeri A, Scheiflinger F, Reipert BM, Malisauskas M. Comparative analysis of marketed factor VIII products: recombinant products are not alike vis-a-vis soluble protein aggregates and subvisible particles. *J Thromb Haemost*. 2018; 16:1176–81.
2. Gouw SC, van der Bom JG, Ljung R, Escuriola C, Cid AR, Claeysens-Donadel S, van Geet C, Kenet G, Makiperna A, Molinari AC, Muntean W, Kobelt R, Rivard G, Santagostino E, Thomas A, van den Berg HM. Factor VIII products and inhibitor development in severe hemophilia A. *N Engl J Med*. 2013; 368:231–9.
3. Calvez T, Chambost H, Claeysens-Donadel S, d'Oiron R, Goulet V, Guillet B, Heritier V, Milien V, Rothchild C, Roussel-Robert V, Vinciguerra C,

Goudemand J. Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A. *Blood*. 2014; 124:3398–408.

4. Frase M. Safely Storing Factor at Home. HemAware. 2010 [cited 2018 Jul 9]. Available from: <https://hemaware.org/bleeding-disorders-z/safely-storing-factor-home>
5. Roberts CJ. Therapeutic Protein Aggregation: Mechanisms, Design, and Control. *Trends Biotechnol*. 2014; 32:372–80.

Disclosure of conflict of interest

MM has acted as consultant or participated in advisory panels for Bioverativ, CSL Behring, NovoNordisk and Shire. MM is also the project leader for EUHASS which receives funding from Bayer, Biotest, BPL, CSL Behring, Grifols, Kedrion, LFB, NovoNordisk, Octapharma, Pfizer, Roche, Shire and Sobi
AF provides compensated consultancy services to the manufacturers of Factor VIII concentrates.